Cargando…

Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors

BACKGROUND: Despite the important implications of lipohypertrophy for diabetes control, there is a dearth of information and research about the subject in children. The aim of this study was to study the prevalence of lipohypertrophy in children with type 1 diabetes, and to evaluate the associated f...

Descripción completa

Detalles Bibliográficos
Autores principales: Omar, Magdy A, El-Kafoury, Ahmed A, El-Araby, Ramy I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186759/
https://www.ncbi.nlm.nih.gov/pubmed/21838879
http://dx.doi.org/10.1186/1756-0500-4-290
_version_ 1782213297895899136
author Omar, Magdy A
El-Kafoury, Ahmed A
El-Araby, Ramy I
author_facet Omar, Magdy A
El-Kafoury, Ahmed A
El-Araby, Ramy I
author_sort Omar, Magdy A
collection PubMed
description BACKGROUND: Despite the important implications of lipohypertrophy for diabetes control, there is a dearth of information and research about the subject in children. The aim of this study was to study the prevalence of lipohypertrophy in children with type 1 diabetes, and to evaluate the associated factors. FINDINGS: 119 children coming for regular follow up in the diabetes clinic were examined for the presence of lipohypertrophy by inspection and palpation. The last 4 readings of glycated hemoglobin (HbA1c) levels and other factors that may affect lipohypertrophy were documented. RESULTS: The patient's age ranged from 2 months to 21 years with a median of 10 years (inter-quartile range = 6). Lipohypertrophy occurred in 54.9% of patients, more commonly in males (62.7%) vs. females (48.4%) (P = 0.074). Grade 1 lipohypertrophy occurred in 42.5% and grade 2 in 12.4%. Lipohypertrophy was related significantly to the dose of insulin units per kg of body weight (Odds ratio [OR] = 16.4; 95% CI, 2.2 - 124.6; P = 0.007), the duration of diabetes, [OR] = 1.16; 95% CI, 1.05 - 1.32; P = 0.004)), and the body mass index (BMI) [OR] = 1.68; 95% CI, 1.25 - 2.15; P = 0.006). The mean HbA1c levels of patients with grade 1 and grade 2 lipohypertrophy did not differ from diabetics without lipohypertrophy (F = 0.178, P = 0.837) CONCLUSIONS: The presence of lipohypertrophy was significantly associated with the duration of diabetes and the body mass index. Children with lipohypertrophy needed a significantly higher dose of insulin units/kg of body weight to achieve fair control compared to children without lipohypertrophy. Further studies are needed to ascertain the clinical meaning of these findings.
format Online
Article
Text
id pubmed-3186759
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31867592011-10-05 Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors Omar, Magdy A El-Kafoury, Ahmed A El-Araby, Ramy I BMC Res Notes Short Report BACKGROUND: Despite the important implications of lipohypertrophy for diabetes control, there is a dearth of information and research about the subject in children. The aim of this study was to study the prevalence of lipohypertrophy in children with type 1 diabetes, and to evaluate the associated factors. FINDINGS: 119 children coming for regular follow up in the diabetes clinic were examined for the presence of lipohypertrophy by inspection and palpation. The last 4 readings of glycated hemoglobin (HbA1c) levels and other factors that may affect lipohypertrophy were documented. RESULTS: The patient's age ranged from 2 months to 21 years with a median of 10 years (inter-quartile range = 6). Lipohypertrophy occurred in 54.9% of patients, more commonly in males (62.7%) vs. females (48.4%) (P = 0.074). Grade 1 lipohypertrophy occurred in 42.5% and grade 2 in 12.4%. Lipohypertrophy was related significantly to the dose of insulin units per kg of body weight (Odds ratio [OR] = 16.4; 95% CI, 2.2 - 124.6; P = 0.007), the duration of diabetes, [OR] = 1.16; 95% CI, 1.05 - 1.32; P = 0.004)), and the body mass index (BMI) [OR] = 1.68; 95% CI, 1.25 - 2.15; P = 0.006). The mean HbA1c levels of patients with grade 1 and grade 2 lipohypertrophy did not differ from diabetics without lipohypertrophy (F = 0.178, P = 0.837) CONCLUSIONS: The presence of lipohypertrophy was significantly associated with the duration of diabetes and the body mass index. Children with lipohypertrophy needed a significantly higher dose of insulin units/kg of body weight to achieve fair control compared to children without lipohypertrophy. Further studies are needed to ascertain the clinical meaning of these findings. BioMed Central 2011-08-12 /pmc/articles/PMC3186759/ /pubmed/21838879 http://dx.doi.org/10.1186/1756-0500-4-290 Text en Copyright ©2011 Omar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Omar, Magdy A
El-Kafoury, Ahmed A
El-Araby, Ramy I
Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors
title Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors
title_full Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors
title_fullStr Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors
title_full_unstemmed Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors
title_short Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors
title_sort lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186759/
https://www.ncbi.nlm.nih.gov/pubmed/21838879
http://dx.doi.org/10.1186/1756-0500-4-290
work_keys_str_mv AT omarmagdya lipohypertrophyinchildrenandadolescentswithtype1diabetesandtheassociatedfactors
AT elkafouryahmeda lipohypertrophyinchildrenandadolescentswithtype1diabetesandtheassociatedfactors
AT elarabyramyi lipohypertrophyinchildrenandadolescentswithtype1diabetesandtheassociatedfactors